PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1791881

Structure-function relationships in human immunoglobulins.

R Jefferis
View original source ↗Export metadata ↓

Abstract

The majority of monoclonal antibodies having potential for in vivo diagnostic and therapeutic applications, in man, are of mouse or rat origin. They need to be "humanized" to prevent rejection by the human immune system and, where indicated, to activate host effector mechanisms. Genetic engineering techniques have made all nine human immunoglobulin isotypes available, but we do not have a sufficient understanding of their functional activities to determine which isotype may be optimal for a given application. This review discusses the major effector systems identified and recent studies directed at defining the structural basis for immunoglobulin recognition by Fc receptors and complement. Site-directed mutagenesis has demonstrated that ligand-binding sites can be modulated by single amino acid substitutions. Additionally, it has been shown that glycosylation is essential for full functional activity. It appears that there is a subtle interplay between the polypeptide and oligosaccharide structures to generate these ligand binding sites. Taken together, these findings suggest that it will be possible to generate "customized" antibody molecules having a pre-determined profile of effector functions.

Explore related subjects

Complement C1GlycosylationHumansImmunoglobulinsProtein BindingReceptors, FcStructure-Activity RelationshipJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Jefferis. 1991. Structure-function relationships in human immunoglobulins.. https://pubmed.ncbi.nlm.nih.gov/1791881/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Genetic deficiencies of complement.

Genetic deficiencies of proteins of the complement system are associated with diverse clinical phenotypes. These clinical manifestations vary as a function of the specific component that is missing. Molecular and cellular biological methods, coupled with more intensive clinical studies, have defined the pathophysiological basis for this set of genetic disorders. Insights into the normal function of complement and its role in immunopathology have been derived from the extensive work in this field during the past few years.

Complement C1↗
PubMed1995

Inhibition of activation of human T lymphocytes by the complement C1 esterase inhibitor.

The major histocompatibility complex (MHC) class I molecules have been shown to be substrates to both of the complement C1 esterases. The effect of a C1 esterase-mediated cleavage of the MHC class I molecules on the activation process of lymphocytes was investigated by including the complement C1 esterase inhibitor (C1-Inh) in the medium during activation of human peripheral lymphocytes by staphylococcal enterotoxin A (SEA). The C1-Inh was shown to inhibit the activation of both CD4+ and CD8+ cells. No effect on activation of B lymphocytes was recorded, although the complement C1 complex was shown to bind to the B lymphocytes. Furthermore, the C1 complex bound to mononuclear cells was shown to be cleaved into molecular weights corresponding to the activated forms of the C1 esterases. The effect of the C1-Inh was much more pronounced at low cell density and the inhibition was not affected by the addition of interleukin-2 (IL-2). However, the inhibition was reduced when the cells were disturbed by addition of new portions of C1-Inh, 24 and 48 hr after the initiation of the activation. This indicates that the C1-Inh interference with the activation of T lymphocytes is mediated through a mechanism that requires some form of cell contact.

Complement C1↗
PubMed1993

Genetic deficiencies of the complement system and association with disease--early components.

Genetic deficiency of one of the early components of the classical pathway of complement (C1q, C1r, C1s, C4 and C2) is often associated with clinical symptoms and immunochemical abnormalities common in idiopathic autoimmune diseases, such as lupus erythematosus, but also with an increased incidence of various, local and generalized infections. These observations are consistent with the current view of the complement system's role in handling immune complexes and combating microbial invasion. However, the absence of absolute correlations in these experiments of nature suggests that genetic defects of the classical pathway act only epistatically to other host factors and the primary etiologies of the associated diseases. In contrast, the strong association of properdin and factor D deficiency with serious infections caused by encapsulated Gram-negative bacteria suggests a more immediate involvement of the alternative pathway in a specific segment of immunity and its pathology. This concept is also supported by the primordial role of the alternative pathway in the evolution of the complement system and the apparent lethality of factor B deficiency. The gene structures of most of these early components have now been elucidated providing the basis for detailed analyses of the defective alleles, the determination of carrier status, and prenatal diagnosis.

Complement C1↗